Changes in Hong Kong stocks | Zaiding Pharmaceutical (09688) rose nearly 4%, and total revenue in the first quarter increased 22% year on year to US$106 million

The Zhitong Finance App learned that Zaiding Pharmaceutical (09688) rose nearly 4%. As of press release, it had risen 3.8% to HK$23.2, with a turnover of HK$65.1923 million.

According to the news, Zaiding Pharmaceutical announced unaudited results for the three months ended March 31, 2025, with total revenue of US$106 million, an increase of 22.19% over the previous year; R&D expenditure was US$607.29 million, an increase of 11.13% over the previous year. Among them, net product revenue for the first quarter of 2025 was US$105.7 million, compared to US$87.1 million for the same period in 2024, an increase of 21% year-on-year, and a year-on-year increase of 23% at a fixed exchange rate. This increase was mainly driven by sales growth in Wei Weijia, Zele, and New Zealand Raleigh.

Josh Smiley, president and chief operating officer of Zaiding Pharmaceuticals, said that looking forward to the future, late-stage pipeline products, including pemastuzumab and KarXT, will work with Wei Weijia to drive the next round of growth in the company's performance. At the same time, we continue to optimize our financial situation. Operating losses narrowed 20% year on year and 25% year on year after adjustment, and are steadily moving towards the goal of achieving profit in the fourth quarter of 2025.